07:42 AM EST, 01/31/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma, a type of liver cancer.

The company said the recommendation is based on a phase 3 trial, which showed statistically significant and clinically meaningful improvement in the primary endpoint of overall survival.

The committee opinion will be reviewed by the European Commission, which has the authority to approve medicines in the European Union, the company said.